Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:XPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeXPHSPDR S&P Pharmaceuticals ETF$58.86-0.4%$55.98$39.10▼$60.73$361.99M0.6183,377 shs19,161 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceXPHSPDR S&P Pharmaceuticals ETF-0.41%-1.47%+2.78%+3.55%+51.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeXPHSPDR S&P Pharmaceuticals ETF$58.86-0.4%$55.98$39.10▼$60.73$361.99M0.6183,377 shs19,161 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceXPHSPDR S&P Pharmaceuticals ETF-0.41%-1.47%+2.78%+3.55%+51.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceXPHSPDR S&P Pharmaceuticals ETF 2.62Moderate Buy$58.86N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookXPHSPDR S&P Pharmaceuticals ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateXPHSPDR S&P Pharmaceuticals ETFN/AN/A14.28N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthXPHSPDR S&P Pharmaceuticals ETF$0.370.63%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipXPHSPDR S&P Pharmaceuticals ETFN/AInsider OwnershipCompanyInsider OwnershipXPHSPDR S&P Pharmaceuticals ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableXPHSPDR S&P Pharmaceuticals ETFN/A6.15 millionN/ANot OptionableXPH HeadlinesRecent News About These CompaniesIs State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?April 3, 2026 | zacks.comShould You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?March 30, 2026 | zacks.comSPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0610March 23, 2026 | msn.comUS and China clash over fentanyl and tariffs at global drugs meetingMarch 9, 2026 | reuters.comThese 5 Undervalued ETFs Could Be Bargains Right NowFebruary 26, 2026 | 247wallst.comXPH’s 29% Run Looks Tempting, But The 5y Chart Is A WarningFebruary 18, 2026 | 247wallst.comXPH's 29% Run Looks Tempting, But The 5y Chart Is A WarningFebruary 18, 2026 | 247wallst.comIs State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?January 29, 2026 | zacks.comShould You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?January 28, 2026 | zacks.comXPH: Healthcare Dashboard For JanuaryJanuary 16, 2026 | seekingalpha.comState Street® SPDR® S&P® Pharmaceuticals ETFJanuary 11, 2026 | markets.businessinsider.com3 Undervalued ETFs to Buy Before 2026December 10, 2025 | zacks.comPharma ETF (XPH) Hits a New 52-Week HighDecember 9, 2025 | zacks.comUS and UK agree zero-tariffs on pharmaceuticalsDecember 1, 2025 | news.sky.comNUS, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources sayDecember 1, 2025 | reuters.comShould You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?November 28, 2025 | zacks.comIs State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?November 27, 2025 | zacks.comBig pharma hits a record high as FDA picks new drug regulatorNovember 12, 2025 | msn.comXPH: Small-Cap Pharma Turns Higher, At Long LastOctober 14, 2025 | seekingalpha.comShort bets on S&P 500 Healthcare sector rises marginally to 1.91% in September; MRNA remains most shorted stockOctober 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXPH Company DescriptionsSPDR S&P Pharmaceuticals ETF NYSEARCA:XPH$58.86 -0.24 (-0.41%) As of 05/14/2026 04:10 PM EasternSPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.